Insilico Medicine
Biotechnology company that applies generative AI to target discovery and molecule design; offices in Boston and Hong Kong (Wikipedia). Sponsor of the rentosertib-phase-2a trial, where its platform supplied both the target (TNIK) and the drug. Thin node.